LADENBURG THALM/SH SH Begins Coverage on Calidi Biotherapeutics (NYSEAMERICAN:CLDI)

LADENBURG THALM/SH SH assumed coverage on shares of Calidi Biotherapeutics (NYSEAMERICAN:CLDI) in a research report report published on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $1.00 target price on the stock.

Several other brokerages have also recently issued reports on CLDI. Robert W. Baird dropped their target price on Calidi Biotherapeutics from $4.50 to $2.00 and set an outperform rating for the company in a report on Wednesday, May 15th. HC Wainwright decreased their target price on Calidi Biotherapeutics from $11.00 to $2.00 and set a buy rating on the stock in a research note on Thursday, March 21st.

Calidi Biotherapeutics Stock Down 3.3 %

Shares of NYSEAMERICAN:CLDI opened at $0.20 on Thursday. Calidi Biotherapeutics has a 12-month low of $0.14 and a 12-month high of $13.79.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its earnings results on Tuesday, May 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.07. Sell-side analysts anticipate that Calidi Biotherapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Calidi Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Spectrum Asset Management Inc. NB CA acquired a new stake in shares of Calidi Biotherapeutics in the 1st quarter worth approximately $94,000. Apollo Management Holdings L.P. acquired a new stake in shares of Calidi Biotherapeutics in the 1st quarter worth approximately $71,000. Evermay Wealth Management LLC purchased a new stake in Calidi Biotherapeutics in the 1st quarter valued at approximately $36,000. Finally, Magnetar Financial LLC purchased a new stake in Calidi Biotherapeutics in the 1st quarter valued at approximately $36,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.